Nehal J. Lakhani

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Eric J. Sherman, Bruce Robinson et al. · New England Journal of Medicine · 2020 · 773 citations · Full text

Medicine, Endocrinology, Oncology +16

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik et al. · Journal of Clinical Oncology · 2019 · 590 citations · Full text

Pharmacy, Oncology, Pharmacology +17

ANG1005, a Brain-Penetrating Peptide–Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases

Priya Kumthekar, Shou‐Ching Tang, Andrew Brenner et al. · Clinical Cancer Research · 2020 · 243 citations

Medicine, Oncology, Pharmacology +17

Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas

Howard A. Fine, Patrick Y. Wen, Elizabeth A. Maher et al. · Journal of Clinical Oncology · 2003 · 174 citations

Medicine, Oncology, Pharmacology +17

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

William L. Dahut, Nehal J. Lakhani, James L. Gulley et al. · Cancer Biology & Therapy · 2006 · 156 citations

Pharmacy, Oncology, Pharmacology +15